Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD)

Summary

This protocol is an extension of protocol 0002, Proof of Concept and Dose Ranging Study of carbidopa-levodopa in Neovascular AMD. that is a 3 month study of escalating doses of carbidopa-levodopa in neovascular AMD. This trial is a 9 month extension for patients who successfully complete protocol 0002 and wish to continue carbidopa-levodopa therapy. It will use the two higher dose regimens of protocol 0002. these will be assigned according to how well the higher dose was tolerated in protocol 0002.

Timeline

Start

2017-08-01

Primary completion

2020-07-09

Completion

2020-07-09

Drugs

Indications